2013 Fiscal Year Final Research Report
Development of novel therapy for hormone-refractory prostate cancer patients through targeting 5-HT receptor and mast cells
Project/Area Number |
23590387
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Human pathology
|
Research Institution | Tohoku University |
Principal Investigator |
NAKAMURA Yasuhiro 東北大学, 医学(系)研究科(研究院), 准教授 (80396499)
|
Co-Investigator(Renkei-kenkyūsha) |
SASANO Hironobu 東北大学, 大学院医学系研究科, 教授 (50187142)
|
Project Period (FY) |
2011 – 2013
|
Keywords | 前立腺癌 / セロトニン受容体 / エストロゲン受容体 / 肥満細胞 |
Research Abstract |
ER beta is well known to play important roles in the pathogenesis of prostate cancer. Increased expression of 5-HT receptor, especially type 4 (5-HTR4), has been also proposed to be involved in the pathogenesis and peritumoral mast cells have been known to be histopatohologically present. In our immunohistochemical analysis (n=112), 5-HTR4 immunoreactivity was detected in 34% cases, and its immunoreactivity was significantly correlated with that of ER beta. Peritumoral mast cells, a potential site of serotonin production, were abundant within the tissues. 24h incubation of LNCaP cells with 5-HTR4 agonist increased the expression level of ER beta mRNA, while inhibited migration of cancer cells compared to controls.These findings indicated that 5-HTR4 may be involved in the pathogenesis of human prostate cancer cells possibly through 5-HT secreted by peritumoral mast cells.
|
-
[Presentation] ヒト前立腺癌組織での5-HTR4によるエストロゲン受容体β(ERβ)の発現調節2014
Author(s)
中村保宏, 伊勢和恵, フェリゾラサウロ, 齊藤涼子, 佐藤聡子, 前川尚志, 深谷佐智子, 佐藤直実, 勝罵浩紀, 柴原裕紀子, 板倉裕子, 谷内真司, 笠島敦子, 藤島史喜, 渡辺みか, 荒井陽一, 笹野公伸
Organizer
第103回日本病理学会総会
Place of Presentation
広島
Year and Date
2014-04-25
-
-
-